Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity
Open Access
- 1 October 1995
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 72 (4), 869-874
- https://doi.org/10.1038/bjc.1995.426
Abstract
The present studies were initiated to quantitate the oxygen dependence of bioreductive metabolism-induced binding of EF5, a pentafluorinated derivative of the 2-nitroimidazole, etanidazole. Two different assays were compared: first, radioactive drug incorporation into cell lysates, which provides a direct measure of drug metabolism or uptake; second, monoclonal antibody detection of cellular macromolecular adducts of EF5 after whole cell permeabilisation and fixing. The antibodies (a single clone designated ELK3-51) were conjugated with the fluorescent dye Cy3, with fluorescence determined by fluorescence microscopy and flow cytometry. For the two cell lines tested (V79 Chinese hamster fibroblasts and 9L rat glioma), the oxygen dependence of binding was found to be the same for the two techniques. Using the antibody binding technique, the fluorescence signal was highly reproducible between experiments, resistant to light or chemical bleaching and stable over time following cell or tissue staining. Flow cytometric analysis of cells from rat 9L tumours treated with EF5 in vivo or in vitro showed a distribution of fluorescent signal which was very compatible, on both a relative and absolute basis, with the in vitro results. Our results indicate that immunofluorescent techniques provide a quantitative assay for bioreductive drug adducts, and therefore may be able to measure the absolute oxygen concentration distribution in cell populations and tissues of interest.Keywords
This publication has 25 references indexed in Scilit:
- The role of specific reductases in the intracellular activation and binding of 2-nitroimidazolesInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Bioreductive metabolism of AF-2 [2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles: Implications for use as hypoxic cell markersBiochemical Pharmacology, 1993
- Retention of misonidazole in normal and malignant tissues: Interplay of hypoxia and reductasesInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Keynote address: Bioreductive mechanismsInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Importance of thiols in the reductive binding of 2-nitroimidazoles to macromoleculesBiochemical Pharmacology, 1990
- Cyanine dye labeling reagents—carboxymethylindocyanine succinimidyl estersCytometry, 1990
- Combined radiation-protective and radiation-sensitizing agents IV: Measurement of intracellular protector concentrationsInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Retardation of immunofluorescence fading during microscopy.Journal of Histochemistry & Cytochemistry, 1985
- The disaggregation, separation and identification of cells from irradiated and unirradiated EMT6 mouse tumorsInternational Journal of Radiation Oncology*Biology*Physics, 1980
- Hypoxic Sensitizers — Implications for Radiation TherapyNew England Journal of Medicine, 1979